Correction of risk factors in patients with atrial fibrillation


DOI: https://dx.doi.org/10.18565/therapy.2023.8.14-19

Prekina V.I., Kunyaeva T.A., Shokina S.V., Samolvina O.G., Skopina Yu.A.

N.P. Ogarev National Research Mordovian State University, Saransk
Abstract. Identification and control of cardiovascular risk factors in patients with atrial fibrillation (AF) is an actual problem.
The aim: to study the prevalence of risk factors and comorbid conditions in AF patients and to perform the analysis of the control of arterial hypertension (AH) and lipid spectrum indexes in these patients.
Material and methods. Retrospective analysis of medical records of 140 patients with AF (57 male and 83 female patients) receiving medical care in outpatient conditions was carried out. Average age of the patients was 68,26±1,01 (46–84) years old. Risk factors and comorbid conditions were identified in examined persons, and the quality of hypertension and dyslipidemia control was assessed in terms of achieving target levels of blood pressure and plasma lipids depending on the cardiovascular risk (CVR) degree.
Results. The most common risk factors for AF development in the studied patients were hypertension (93%) and dyslipidemia (75%). In 55,38% of cases, hypertension was uncontrolled due to the use of suboptimal doses and insufficient amounts of antihypertensive drugs. 96,43% were categorized as high or very high CVR degree. The majority of patients in this group (92.59%) received statins, but the target LDL cholesterol level was achieved only in 4,44% of cases. The main reasons for poor lipid control were low-dose statins use and use of monotherapy.
Conclusion. Optimization of antihypertensive and lipid-lowering therapy is an important reserve in improving the prognosis of patients with AF.
Keywords: risk factors for atrial fibrillation, arterial hypertension, dyslipidemia, atrial fibrillation
Read entire article

Literature

1. Аракелян М.Г., Бокерия Л.А., Васильева Е.Ю. с соавт. Фибрилляция и трепетание предсердий. Клинические рекомендации 2020. Российский кардиологический журнал. 2021; 26(7): 190–260. [Arakelyan M.G., Bockeria L.A., Vasilieva E.Yu. et al. 2020 Clinical guidelines for Atrial fibrillation and atrial flutter. Rossiyskiy kardiologicheskiy zhurnal = Russian Journal of Cardiology. 2021; 26(7): 2021; 26(7): 190–260 (In Russ.)]. https://dx.doi.org/10.15829/1560-4071-2021-4594. EDN: FUZAAD.


2. Hindricks G., Potpara T., Dagres N. с соавт. Рекомендации ESC 2020 по диагностике и лечению пациентов с фибрилляцией предсердий, разработанные совместно с европейской ассоциацией кардиоторакальной хирургии (EACTS). Российский кардиологический журнал. 2021; 26(9): 234–329. [Hindricks G., Potpara T., Dagres N. et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Rossiyskiy kardiologicheskiy zhurnal = Russian Journal of Cardiology. 2021; 26(9): 234–329 (In Russ.)]. https://dx.doi.org/10.15829/1560-4071-2021-4701. EDN: NNLETB.


3. Ардашев А.В., Беленков Ю.Н., Матюкевич М.Ч., Снежицкий В.А. Фибрилляция предсердий и смертность: прогностические факторы и терапевтические стратегии. Кардиология. 2021; 61(2): 91–98. [Ardashev A.V., Belenkov Yu.N., Matsiukevich M.C., Snezhitskiy V.A. Atrial fibrillation and mortality: Prognostic factors and direction of prevention. Kardiologiya = Cardiology. 2021; 61(2): 91–98 (In Russ.)]. https://dx.doi.org/10.18087/cardio.2021.2.n1348. EDN: XULLPW.


4. Ежов М.В., Кухарчук В.В., Сергиенко И.В. с соавт. Нарушения липидного обмена. Клинические рекомендации 2023. Российский кардиологический журнал. 2023; 28(5): 250–297. [Ezhov M.V., Kukharchuk V.V., Sergienko I.V. et al. Disorders of lipid metabolism. Clinical Guidelines 2023. Rossiyskiy kardiologicheskiy zhurnal = Russian Journal of Cardiology. 2023; 28(5): 250–297 (In Russ.)]. https://dx.doi.org/10.15829/1560-4071-2023-5471. EDN: YVZOWJ.


5. Forouzanfar M.H., Liu P., Roth G.A., et al. Global burden of hypertension and systolic blood pressure of at least 110 to 115 mm Hg, 1990–2015. JAMA. 2017; 317(2): 165–82. https://dx.doi.org/10.1001/jama.2016.19043.


6. Кобалава Ж.Д., Конради А.О., Недогода С.В. с соавт. Артериальная гипертензия у взрослых. Клинические рекомендации 2020. Российский кардиологический журнал. 2020; 25(3): 149–218. [Kobalava Z.D., Konradi A.O., Nedogoda S.V. et al. Arterial hypertension in adults. Clinical guidelines 2020. Rossiyskiy kardiologicheskiy zhurnal = Russian Journal of Cardiology. 2020; 25(3): 149–218 (In Russ.)]. https://dx.doi.org/10.15829/1560-4071-2020-3-3786. EDN: TCRBRB.


7. Денисова А.Р., Солнцева Т.Д., Зарманбетова А.С. с соавт. Частота развития сердечно-сосудистых осложнений у больных с неконтролируемым течением артериальной гипертонии. Терапевтический архив. 2022; 94(1): 94–99. [Denisova AR, Solntseva TD, Zarmanbetova AS, Tkacheva AA, Sivakova OA, Chazova IE. The incidence of cardiovascular and cerebrovascular complications in patients with uncontrolled hypertension. Terapevticheskiy arkhiv = Therapeutic Archive. 2022; 94(1): 94–99. https://dx.doi.org/10.26442/00403660.2022.01.201395. EDN: JIIRBE.


8. Noubiap J.J., Nansseu J.R., Nyaga U.F. et al. Global prevalence of resistant hypertension: A meta-analysis of data from 3.2 million patients. Heart. 2019; 105(2): 98–105. https://dx.doi.org/10.1136/heartjnl-2018-313599.


9. Кузьмин O.Б., Жежа В.В., Ландарь Л.Н., Салова О.A. Резистентная артериальная гипертония у пациентов с хронической болезнью почек: распространенность, прогностическое значение, причины и подходы к антигипертензивной терапии. Нефрология. 2019; 23(1): 37–44. [Kuzmin O.B., Zhezha V.V., Landar L.N., Salova O.A. Resistant arterial hypertension in patients with chronic kidney disease: Prevalence, prognostic significance, reasons and approaches to antihypertensive therapy. Nefrologiya = Nephrology (Saint Petersburg). 2019; 23(1): 37–44 (In Russ.)]. https://dx.doi.org/10.24884/1561-6274-2019-23-1-37-44. EDN: YZPWUX.


About the Autors

Valentina I. Prekina, PhD in Medical Sciences, associate professor, associate professor of the Department of outpatient therapy, N.P. Ogarev National Research Mordovia State University. Address: 430005, Saransk, 68 Bolshevikskaya St.
E-mail: vprekina@mail.ru
ORCID: https://orcid.org/0000-0002-2306-722X
Tatyana A. Kunyaeva, PhD in Medical Sciences, associate professor of the Department of outpatient therapy,
N.P. Ogarev National Research Mordovia State University, chief freelance specialist-therapist of the Ministry of Healthcare of the Republic of Mordovia, chief freelance specialist of the Ministry of Healthcare of Russia for the Volga Federal District. Address: 430005, Saransk, 68 Bolshevikskaya St.
E-mail: kunya_eva@mail.ru
ORCID: https://orcid.org/0000-0003-4245-4265
Svetlana V. Shokina, PhD in Medical Sciences, associate professor of the Department of outpatient therapy, N.P. Ogarev National Research Mordovia State University. Address: 430005, Saransk, 68 Bolshevikskaya St.
E-mail: sveti-kh@mail.ru
ORCID: https://orcid.org/0000-0001-8650-1778
Olga G. Samolkina, PhD in Medical Sciences, associate professor of the Department of outpatient therapy, N.P. Ogarev National Research Mordovia State University. Address: 430005, Saransk, 68 Bolshevikskaya St.
E-mail: olgasamolk@rambler.ru
ORCID: https://orcid.org/0000-0002-5486-2437
Yulia A. Skopina, PhD in Medical Sciences, associate professor of the Department of outpatient therapy, N.P. Ogarev National Research Mordovia State University. Address: 430005, Saransk, 68 Bolshevikskaya St.
E-mail:skopina@bk.ru
ORCID: https://orcid.org/0000-0001-7598-5690


Similar Articles

Back to Content

Бионика Медиа